Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Northwest Biotherapeutics, Inc. (NWBO : OTC)

• Company Description    Northwest Biotherapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing immunotherapy products that safely generate and enhance immune system responses to treat cancer. Number of Employees: 20

• Price / Volume Information    Yesterday's Closing Price: $0.68 Daily Weekly Monthly 20 Day Moving Average: 9,644,931 shares Shares Outstanding: 1,012.83 (millions) Market Capitalization: $688.62 (millions) Beta: 0.05 52 Week High: $2.05 52 Week Low: $0.59 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -28.05% -18.97% 12 Week -22.43% -14.73% Year To Date -2.87% 21.31%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4800 MONTGOMERY LANE SUITE 800 - BETHESDA,MD 20814 USA ph: 240-497-9024 fax: 240-627-4121 lgoldman@nwbio.com http://www.nwbio.com

• General Corporate Information    Officers Linda F. Powers - President and Chief Executive Officer Alton L. Boynton - Director Navid Malik - Director Jerry Jasinowski - Director J. Cofer Black - Director Peer Information Northwest Biotherapeutics, Inc. (CORR.) Northwest Biotherapeutics, Inc. (RSPI) Northwest Biotherapeutics, Inc. (CGXP) Northwest Biotherapeutics, Inc. (BGEN) Northwest Biotherapeutics, Inc. (GTBP) Northwest Biotherapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 66737P600 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/15/22 Share - Related Items Shares Outstanding: 1,012.83 Most Recent Split Date: 9.00 (0.06:1) Beta: 0.05 Market Capitalization: $688.62 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: 3.57 Price / Sales: 456.65 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: 68.62% vs. Previous Quarter: -% ROE 03/31/22 - -75.45 12/31/21 - -63.48 09/30/21 - - ROA 03/31/22 - 529.04 12/31/21 - 552.82 09/30/21 - -766.65 Current Ratio 03/31/22 - 0.07 12/31/21 - 0.13 09/30/21 - 0.02 Quick Ratio 03/31/22 - 0.07 12/31/21 - 0.13 09/30/21 - 0.02 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - -15,549.93 Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - -15,549.93 Pre-Tax Margin 03/31/22 - 14,459.80 12/31/21 - 17,823.48 09/30/21 - -15,549.93 Book Value 03/31/22 - -0.12 12/31/21 - -0.13 09/30/21 - -0.33 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - -

Powered by Zacks Investment Research ©